Progyny, Inc.

NasdaqGS:PGNY Lagerbericht

Marktkapitalisierung: US$1.2b

Progyny Management

Management Kriterienprüfungen 4/4

Progyny CEO ist Pete Anevski , ernannt in Jan 2022, hat eine Amtszeit von 2.83 Jahren. Die jährliche Gesamtvergütung beträgt $1.09M , bestehend aus 45.7% Gehalt und 54.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.18% der Aktien des Unternehmens, im Wert von $2.15M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.8 Jahre bzw. 7.7 Jahre.

Wichtige Informationen

Pete Anevski

Geschäftsführender

US$1.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts45.7%
Amtszeit als Geschäftsführer2.8yrs
Eigentum des Geschäftsführers0.2%
Durchschnittliche Amtszeit des Managements2.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder7.7yrs

Jüngste Management Updates

Recent updates

Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively

Nov 21
Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively

Progyny: After A Terrible Year, I'm Out (Rating Downgrade)

Nov 18

Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital

Oct 21
Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital

Progyny: Poor Year Raises Concerns For Future (Downgrade)

Oct 15

Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Sep 29
Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Progyny: Downgrading As Uncertainties Increase

Aug 15

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Aug 11
Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Jul 20
At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Progyny: Recent Stock Decline Provides Buying Opportunity

Jul 12

Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Jun 23
Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore

Jun 10

Progyny: No Change To Long-Term Outlook

Jun 04

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Apr 29
Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Apr 03
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Mar 15

Progyny: Long-Term Thesis Still Intact

Mar 09

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Mar 01
Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Jan 07
Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Dec 11
Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Nov 08
Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Aug 24
Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Aug 06
There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

May 06
Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Jan 25
When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Dec 12
Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Pete Anevski im Vergleich zu den Einnahmen von Progyny verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

US$57m

Jun 30 2024n/an/a

US$63m

Mar 31 2024n/an/a

US$61m

Dec 31 2023US$1mUS$500k

US$62m

Sep 30 2023n/an/a

US$52m

Jun 30 2023n/an/a

US$49m

Mar 31 2023n/an/a

US$43m

Dec 31 2022US$69mUS$500k

US$30m

Sep 30 2022n/an/a

US$42m

Jun 30 2022n/an/a

US$46m

Mar 31 2022n/an/a

US$56m

Dec 31 2021US$786kUS$425k

US$66m

Sep 30 2021n/an/a

US$90m

Jun 30 2021n/an/a

US$78m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$910kUS$425k

US$46m

Sep 30 2020n/an/a

US$3m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$5mUS$375k

-US$9m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

US$1m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$682kUS$325k

-US$6m

Vergütung im Vergleich zum Markt: PeteDie Gesamtvergütung ($USD1.09M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD3.20M).

Entschädigung vs. Einkommen: PeteDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Pete Anevski (57 yo)

2.8yrs

Amtszeit

US$1,093,512

Vergütung

Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
David Schlanger
Executive Chairman7.7yrsUS$513.57k0.061%
$ 727.2k
Peter Anevski
CEO & Director2.8yrsUS$1.09m0.18%
$ 2.2m
Michael Sturmer
President2.8yrsUS$1.49m0.077%
$ 921.4k
Mark Livingston
Chief Financial Officer4.2yrsUS$1.40m0.052%
$ 621.2k
Allison Swartz
Executive VP2yrsUS$546.22k0.020%
$ 232.5k
Steven Leist
Chief Technology Officerless than a yearkeine Datenkeine Daten
James Hart
Vice President of Investor Relationsno datakeine Datenkeine Daten
Risa Fisher
Chief Marketing Officerno datakeine Datenkeine Daten
Cassandra Pratt
Chief Human Resources Officerno datakeine Datenkeine Daten
Julie Stadlbauer
Chief Business Development Officer2.8yrskeine Datenkeine Daten
Janet Choi
Member of the Medical Advisory Board & Chief Medical Officer1.6yrskeine Datenkeine Daten
Arielle Bogorad
Senior Vice President of Employer Market Strategy2.5yrskeine Datenkeine Daten

2.8yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: PGNYDas Führungsteam des Unternehmens gilt als erfahren (2.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
David Schlanger
Executive Chairman7.7yrsUS$513.57k0.061%
$ 727.2k
Peter Anevski
CEO & Director2.8yrsUS$1.09m0.18%
$ 2.2m
Janet Choi
Member of the Medical Advisory Board & Chief Medical Officerno datakeine Datenkeine Daten
Norman Payson
Independent Director7.9yrsUS$567.30k0.48%
$ 5.7m
Fred Cohen
Independent Director9.7yrsUS$583.35k0.014%
$ 169.6k
Beth Seidenberg
Lead Independent Director14.5yrsUS$653.39k0.30%
$ 3.6m
Kevin Gordon
Independent Director5.1yrsUS$518.30k0.0073%
$ 86.7k
Jeffrey Park
Independent Director5.1yrsUS$606.88k0.014%
$ 169.6k
Alan Copperman
Member of the Medical Advisory Boardno datakeine Datenkeine Daten
Barry Behr
Member of Medical Advisory Boardno datakeine Datenkeine Daten
Brad Kolb
Member of Medical Advisory Boardno datakeine Datenkeine Daten
Gerard Letterie
Member of Medical Advisory Boardno datakeine Datenkeine Daten

7.7yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Durchschnittliches Alter

Erfahrener Vorstand: PGNYDie Vorstandsmitglieder gelten als erfahren (7.7 Jahre durchschnittliche Amtszeit).